Patent ID: 8481277
Filing Date: 2013-07-09
Classification: G01N

Abstract:
1. A method of diagnosing Alzheimer's disease in a subject, which method comprises determining the level of Visinin-like protein 1 (VLP-1) in a sample of biological fluid of a human subject in combination with determining the level of at least one additional marker selected from amyloid-β peptide Aβ1-42, hyperphosphorylated Tau (pTau) and total Tau (tTau); comparing the level of said markers with the levels of the same markers in normal controls, wherein a higher level of VLP-1 in combination with either a lower level of Aβ1-42 or higher level of pTau or higher level of tTau in said subject as compared to normal controls results in a diagnosis for said subject of Alzheimer's disease, and wherein said method provides an improvement in diagnostic accuracy of Alzheimer's disease diagnosis as compared to determinations based on VLP-1 or any of said additional biomarkers alone; and wherein the sample is obtained from cerebrospinal fluid, plasma or serum.